Gabapentin

Generic Name
Gabapentin
Brand Names
Gralise, Neurontin
Drug Type
Small Molecule
Chemical Formula
C9H17NO2
CAS Number
60142-96-3
Unique Ingredient Identifier
6CW7F3G59X
Background

Gabapentin is a structural analogue of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) that was first approved for use in the United States in 1993. It was originally developed as a novel anti-epileptic for the treatment of certain types of seizures - today it is also widely used to treat neuropathic pain. Gabapentin has some stark advantages as compared with other anti-epileptics, such as a relatively benign adverse effect profile, wide therapeutic index, and lack of appreciable metabolism making it unlikely to participate in pharmacokinetic drug interactions.. It is structurally and functionally related to another GABA derivative, pregabalin.

Indication

In the United States, gabapentin is officially indicated for the treatment of postherpetic neuralgia in adults and for the adjunctive treatment of partial-onset seizures, with or without secondary generalization, in patients 3 years of age and older. In Europe, gabapentin is indicated for adjunctive therapy in the treatment of partial-onset seizures, with or without secondary generalization, in patients 6 years of age and older and as monotherapy in patients 12 years of age and older. It is also used in adults for the treatment of various types of peripheral neuropathic pain, such as painful diabetic neuropathy.

Associated Conditions
Partial-Onset Seizures, Peripheral Neuropathic Pain, Postherpetic Neuralgia
Associated Therapies
-

Safety and Efficacy of Gabapentin for Neuropathic Pain in Fabry Disease

Phase 2
Withdrawn
Conditions
Interventions
First Posted Date
2012-04-30
Last Posted Date
2019-05-29
Lead Sponsor
University of Minnesota
Registration Number
NCT01588314
Locations
🇺🇸

University of Minnesota, Fariview, Minneapolis, Minnesota, United States

Gabapentin vs Chlordiazepoxide for Ambulatory Alcohol Withdrawal

Phase 4
Completed
Conditions
Interventions
First Posted Date
2012-04-06
Last Posted Date
2020-08-17
Lead Sponsor
VA Salt Lake City Health Care System
Target Recruit Count
26
Registration Number
NCT01573052
Locations
🇺🇸

George E Wahlen VA Medical Center, Salt Lake City, Utah, United States

Quality of Life Study Using Gabapentin Versus Venlafaxine in Treating Hot Flashes in Patients With Prostate Cancer

Phase 2
Terminated
Conditions
Interventions
First Posted Date
2012-02-15
Last Posted Date
2019-11-21
Lead Sponsor
University of Wisconsin, Madison
Target Recruit Count
5
Registration Number
NCT01533753
Locations
🇺🇸

University of Wisconsin Hospital and Clinics (Carbone Cancer Center), Madison, Wisconsin, United States

Analgesic Effect of Gabapentin in Total Knee Arthroplasty (TKA)

First Posted Date
2012-01-10
Last Posted Date
2014-04-11
Lead Sponsor
Hvidovre University Hospital
Target Recruit Count
300
Registration Number
NCT01507363
Locations
🇩🇰

Dep. of anesthesiology and ortopedic surgery Hvidovre Hospital, Copenhagen, Hvidovre, Denmark

🇩🇰

Dep. of ortopedic surgery, Aalborg Sygehus, Aalborg, Denmark

🇩🇰

Dep. of ortopedic surgery, Esbjerg Sygehus, Esbjerg, Denmark

Therapeutic Interventions For Pain Induced By Vincristine Treatment For Childhood Acute Lymphoblastic Leukemia (ALL)

First Posted Date
2012-01-10
Last Posted Date
2019-06-19
Lead Sponsor
St. Jude Children's Research Hospital
Target Recruit Count
51
Registration Number
NCT01506453
Locations
🇺🇸

St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Steroids Versus Gabapentin

First Posted Date
2011-12-20
Last Posted Date
2017-04-11
Lead Sponsor
Johns Hopkins University
Target Recruit Count
145
Registration Number
NCT01495923
Locations
🇺🇸

Naval Hospital-San Diego, San Diego, California, United States

🇺🇸

Walter Reed National Military Medical Center, Bethesda, Maryland, United States

🇺🇸

Johns Hopkins, Baltimore, Maryland, United States

Analgesia After Total Knee Replacement Surgery

First Posted Date
2011-12-09
Last Posted Date
2015-06-08
Lead Sponsor
St. Antonius Hospital
Target Recruit Count
81
Registration Number
NCT01489631
Locations
🇳🇱

St. Antonius Hospital, Nieuwegein, Netherlands

Efficacy and Safety of Gabapentin in Treating Overactive Bladder

First Posted Date
2011-12-06
Last Posted Date
2017-01-02
Lead Sponsor
Michael E. Chua
Target Recruit Count
94
Registration Number
NCT01486706
Locations
🇵🇭

Comprehensive Pelvic Floor Center- St. Luke's Medical Center, Quezon City, National Capital Region, Philippines

Safety and Efficacy of Gabapen for Pediatric (Regulatory Post Marketing Commitment Plan)

Completed
Conditions
Interventions
First Posted Date
2011-09-27
Last Posted Date
2021-02-03
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Target Recruit Count
82
Registration Number
NCT01441401

Gabapentin's Effects on Insomnia in Patients With Recent Concussion

Phase 1
Completed
Conditions
Interventions
First Posted Date
2011-08-22
Last Posted Date
2023-02-14
Lead Sponsor
State University of New York at Buffalo
Target Recruit Count
21
Registration Number
NCT01421264
Locations
🇺🇸

University at Buffalo, Concussion Clinic, Buffalo, New York, United States

© Copyright 2024. All Rights Reserved by MedPath